Menu ×

HEALTHCARE & PHARMACEUTICAL

Luteinizing Hormone Releasing Hormone (LHRH) Agonists Market Segmentation by Drug Type (Eligard, Zoladex, Lupron, Vantas and Others); by Patient Type (Males and Females); by End Users (Hospitals, Speciality Clinics and Others) - Global Demand Analysis & Opportunity Outlook 2029

  • Text Size:

Extensive insights into the Growth of Luteinizing Hormone Releasing Hormone (LHRH) Agonists Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

Global Luteinizing Hormone Releasing Hormone (LHRH) Agonists Market Highlights 2020-2029

The market for luteinizing hormone releasing hormone agonists is anticipated to record a significant CAGR during the forecast period, i.e., 2021-2029. The LHRH-agonist therapy is widely used for patients with prostate cancer. In males, LHRH agonist manages the growth of prostate cancer by stopping normal hormonal functions in the body. Initially, LHRH agonist stimulates the production of testosterone for a couple of weeks and when the LHRH agonist reaches an elevated level, the human body stops the production of new LHRH. Owing to the consequence, there is no more production of testosterone in the body and low levels of testosterone drops the level of prostate cancer cells in the body. The market is thriving primarily on account of the growing cases of prostate cancer in males.

Luteinizing Hormone Releasing Hormone (LHRH) Agonists Market

The global luteinizing hormone releasing hormone agonists market is segmented by drug type into Eligard, Zoladex, Lupron, Vantas and others. Amongst these segments, the Eligard segment is projected to grab a significant market share in the year 2021. The growth of the segment can be attributed to the rising usage of the drug for the treatment of prostate cancer.

Global Luteinizing Hormone Releasing Hormone (LHRH) Agonists Market Regional Synopsis

Regionally, the global luteinizing hormone releasing hormone agonists market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.

The market for LHRH agonists in North America is anticipated to dominate the market by the end of 2029 owing to the rising incidence rate of prostate cancer in the region along with the increasing investments for the development of targeted drug therapies to treat prostate cancer. Alternatively, the market in the Asia Pacific region is estimated to be the fastest growing by recording a significant CAGR during the forecast period on the back of growing awareness for the treatment of prostate cancer coupled with the improvements in healthcare infrastructure. Further, collaborations of key players with various government institutions for the treatment of prostate cancer along with the presence of online portals providing detailed information regarding luteinizing hormone releasing hormone agonists is also anticipated to foster the market growth over the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT

Luteinizing Hormone Releasing Hormone (LHRH) Agonists Market

The global luteinizing hormone releasing hormone agonists market is further classified on the basis of regions as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis.

Market Segmentation

Our in-depth analysis of the global luteinizing hormone releasing hormone agonists market includes the following segments:

By Drug Type

  • Eligard
  • Zoladex
  • Lupron
  • Vantas
  • Others

By Patient Type

  • Males
  • Females

By End Users

  • Hospitals
  • Specialty Clinics
  • Others

Growth Drivers

  • High Effectiveness of LHRH Agonists in Prostate Cancer
  • Rising Advancements in the Healthcare Industry

Challenges

  • Side Effects Related to LHRH Agonists

Top Featured Companies Dominating the Market

  • F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis
  • Novartis Pharmaceuticals Corporation
  • Siemens Healthcare Private Limited
  • Pfizer Inc.
  • Clovis Oncology
  • Genomic Health, Inc.
  • Myriad Genetics, Inc.
  • MDxHealth
  • Tolmar Pharmaceuticals, Inc.
  • Ferring B.V.

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved